Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Debt: 2013-2025

Historic Non-Current Debt for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $608.6 million.

  • Amphastar Pharmaceuticals' Non-Current Debt rose 2.03% to $608.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $608.6 million, marking a year-over-year increase of 2.03%. This contributed to the annual value of $601.6 million for FY2024, which is 2.04% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Non-Current Debt is $608.6 million, which was up 0.14% from $607.7 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Non-Current Debt ranged from a high of $638.2 million in Q3 2023 and a low of $30.5 million during Q2 2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Non-Current Debt value was $596.4 million (recorded in 2024), while the average stood at $544.4 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Non-Current Debt fell by 12.02% in 2021 and then spiked by 762.31% in 2023.
  • Amphastar Pharmaceuticals' Non-Current Debt (Quarterly) stood at $74.8 million in 2021, then fell by 2.59% to $72.8 million in 2022, then surged by 709.43% to $589.6 million in 2023, then grew by 2.04% to $601.6 million in 2024, then increased by 2.03% to $608.6 million in 2025.
  • Its last three reported values are $608.6 million in Q3 2025, $607.7 million for Q2 2025, and $603.9 million during Q1 2025.